Published in Ann Oncol on April 23, 2013
Prediction of postchemotherapy ovarian function using markers of ovarian reserve. Oncologist (2013) 0.84
Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103. Breast Cancer Res Treat (2014) 0.77
Adjuvant endocrine therapy in premenopausal women with breast cancer. Clin Adv Hematol Oncol (2015) 0.76
Ovarian Function, Not Age, Predicts the Benefit from Ovarian Suppression or Ablation for Premenopausal Women with Breast Cancer. PLoS One (2016) 0.75
Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy. Clin Cancer Res (2015) 0.75
The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients. Oncotarget (2017) 0.75
Prediction of ovarian function in premenopausal breast cancer patients with amenorrhoea after chemotherapy: a simple clinical score. Springerplus (2016) 0.75
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med (2003) 13.81
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol (2009) 6.51
Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol (2006) 3.53
Liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of estradiol and estrone in human plasma. Clin Chem (2003) 2.38
Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab (2008) 2.27
Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids (2007) 1.75
Standardization of steroid hormone assays: why, how, and when? Cancer Epidemiol Biomarkers Prev (2007) 1.74
Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol (2006) 1.55
Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab (2011) 1.45
Deficits in plasma oestradiol measurement in studies and management of breast cancer. Breast Cancer Res (2004) 1.02
Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane. Ann Oncol (2012) 0.86
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 4.67
Transcriptional silencing of Ty1 elements in the RDN1 locus of yeast. Genes Dev (1997) 4.31
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 3.25
Multiple regulators of Ty1 transposition in Saccharomyces cerevisiae have conserved roles in genome maintenance. Genetics (2001) 3.10
The very low-birth-weight rate: Principal predictor of neonatal mortality in industrialized populations. J Pediatr (1980) 2.79
Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol (1994) 2.77
The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med (1996) 2.74
A poly(dT)-stimulated ATPase activity associated with simian virus 40 large T antigen. J Biol Chem (1979) 2.74
Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst (1994) 2.50
Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene (2008) 2.31
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
The measurement and therapeutic implications of circulating tumour cells in breast cancer. Br J Cancer (2006) 2.14
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol (2007) 2.05
Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia (2001) 2.02
Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol (1986) 1.94
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol (2001) 1.89
Prognostic implications of a positive apical margin in radical prostatectomy specimens. J Urol (1997) 1.83
Early endoscopy. A guide to therapy for acute hemorrhage in the upper gastrointestinal tract. Arch Surg (1973) 1.77
New prognostic factors for breast cancer recurrence. Semin Oncol (2001) 1.77
Integrable alpha-amylase plasmid for generating random transcriptional fusions in Bacillus subtilis. J Bacteriol (1986) 1.74
A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol (2000) 1.72
Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res (2001) 1.72
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res (2001) 1.71
Single strand DNA binding of simian virus 40 tumor antigen. J Biol Chem (1979) 1.60
Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol (1998) 1.59
Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest (1985) 1.49
Assessing menstrual cycles with urinary hormone assays. Am J Physiol Endocrinol Metab (2002) 1.46
A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone. Mol Endocrinol (2011) 1.45
Evolution of the high molecular weight glutenin loci of the A, B, D, and G genomes of wheat. Genome (1999) 1.44
Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev (2001) 1.43
Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol (1988) 1.43
Testosterone concentrations in women aged 25-50 years: associations with lifestyle, body composition, and ovarian status. Am J Epidemiol (2001) 1.43
The role of cell envelope phospholipid in the enzymatic synthesis of bacterial lipopolysaccharide. Structural requirements of the phospholipid molecule. J Biol Chem (1966) 1.43
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J (2009) 1.43
Variation in utilization of computed tomography scanning for the investigation of minor head trauma in children: a Canadian experience. Acad Emerg Med (2000) 1.41
Should long-haul flights carry antibiotics on board to treat acute bacterial meningitis and meningococcal septicaemia? Br J Biomed Sci (2008) 1.40
When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol (2001) 1.39
Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen. Clin Pharmacol Ther (2007) 1.39
Small intestinal involvement in visceral leishmaniasis. Am J Gastroenterol (1990) 1.39
We may be lost, but we're sure makin' good time. Cancer Invest (1993) 1.38
False-positive results with chemically modified anti-D do not indicate a need to use a separate, immunologically inert Rh control reagent. Transfusion (1988) 1.38
Blood vessels of human islets of Langerhans are surrounded by a double basement membrane. Diabetologia (2008) 1.37
GAL1-GAL10 divergent promoter region of Saccharomyces cerevisiae contains negative control elements in addition to functionally separate and possibly overlapping upstream activating sequences. Genes Dev (1987) 1.35
Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res (1988) 1.34
Phosphorylation of Pak1 by the p35/Cdk5 kinase affects neuronal morphology. J Biol Chem (2001) 1.32
Role of phospholipids in the enzymatic synthesis of the bacterial cell envelope. Fed Proc (1967) 1.32
Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat (2011) 1.29
Unique basement membrane structure of human pancreatic islets: implications for beta-cell growth and differentiation. Diabetes Obes Metab (2008) 1.28
Association of glutathione S-transferase (GSTM1, T1 and P1) gene polymorphisms with type 2 diabetes mellitus in north Indian population. J Postgrad Med (2010) 1.27
Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med (1996) 1.27
Birds disperse ixodid (Acari: Ixodidae) and Borrelia burgdorferi-infected ticks in Canada. J Med Entomol (2001) 1.26
Diabetes and ethnic minorities. Postgrad Med J (2005) 1.25
Posttranslational regulation of Ty1 retrotransposition by mitogen-activated protein kinase Fus3. Mol Cell Biol (1998) 1.20
Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat (2009) 1.19
Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. Blood (1996) 1.17
Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol (1998) 1.16
Evaluation of socio-economic factors causing discontinuation of epilepsy treatment resulting in seizure recurrence: a study in an urban epilepsy clinic in India. Seizure (2007) 1.15
Menopausal-type symptoms in young breast cancer survivors. Ann Oncol (2006) 1.15
Seroprevalence survey of borreliosis in children with chronic arthritis in British Columbia, Canada. J Rheumatol (1992) 1.14
Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen. Cancer Res (1992) 1.14
Interaction of ustiloxin A with bovine brain tubulin. Biochem Pharmacol (1994) 1.14
Distribution of vibrios in Calcutta environment with particular reference to V. parahaemolyticus. Indian J Med Res (1977) 1.13
Physical map of Salmonella typhimurium LT2 DNA in the vicinity of the proA gene. J Bacteriol (1984) 1.13
Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol (1997) 1.13
Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology (2000) 1.11
Adherence with adjuvant hormonal therapy for breast cancer. Ann Oncol (2009) 1.11
The Sgs1 helicase of Saccharomyces cerevisiae inhibits retrotransposition of Ty1 multimeric arrays. Mol Cell Biol (2001) 1.10
Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor? Mod Pathol (1998) 1.09
Factors related to declining luteal function in women during the menopausal transition. J Clin Endocrinol Metab (2008) 1.07
Technical note: interference of Br-, BrO3-, and ClO3- with DOX determination. J Am Water Works Assoc (1995) 1.07
Outcome of palliative urinary diversion in the treatment of advanced malignancies. Cancer (1999) 1.07
Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol (1995) 1.07
TRPM7 and its potential therapeutic target for periodontal diseases: beyond its role in the dental pulp repair process. Int Endod J (2014) 1.06
Synthesis and evaluation of 1,3 di-substituted schiff, mannich bases and spiro isatin derivatives. J Young Pharm (2010) 1.06
Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line. Cancer Commun (1989) 1.05
Healing flare in skeletal metastases from breast cancer. Radiology (1994) 1.05
Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol (1997) 1.04
New agents and new medical treatments for advanced breast cancer. Semin Oncol (1987) 1.04
Urban-rural differences of gynaecological malignancies in Egypt (1999-2002). BJOG (2009) 1.03
Analysis of transient arrhythmias and conduction disturbances occurring during submaximal treadmill exercise testing. Prog Cardiovasc Dis (1970) 1.03
First isolation of Lyme disease spirochete, Borrelia burgdorferi, from blacklegged tick, Ixodes scapularis, removed from a bird in nova Scotia, Canada. Can Commun Dis Rep (1999) 1.03
Reactivity of monoclonal antibody DF3 with a high molecular weight antigen expressed in human ovarian carcinomas. Cancer Res (1986) 1.03
Platelet activation, upregulation of CD11b/ CD18 expression on leukocytes and increase in circulating leukocyte-platelet aggregates in Indian women chronically exposed to biomass smoke. Hum Exp Toxicol (2006) 1.03
Non-adherence to endocrine therapy for breast cancer. Ann Oncol (2006) 1.03
Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol (2008) 1.02
The Mu strong gyrase-binding site promotes efficient synapsis of the prophage termini. Mol Microbiol (1996) 1.02
Lymph node size does not correlate with the presence of prostate cancer metastasis. Urology (1999) 1.01
Should the age specific prostate specific antigen cutoff for prostate biopsy be higher for black than for white men older than 50 years? J Urol (2000) 1.01
Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med (1996) 1.01
Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin Pharmacol Ther (2011) 1.00
Modeling hot flushes and quality of life in breast cancer survivors. Climacteric (2010) 1.00
Soluble phospholipids enhance factor Xa-catalyzed prothrombin activation in solution. Biochemistry (1996) 1.00